Hizal, M. Et Al. 2022. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.. Future oncology (London, England) , vol.18, no.23 , 2573-2582.

Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... Keskinkılıç, M.(2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.. Future oncology (London, England) , vol.18, no.23, 2573-2582.

Hizal, Mutlu Et Al. "Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.," Future oncology (London, England) , vol.18, no.23, 2573-2582, 2022

Hizal, Mutlu Et Al. "Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.." Future oncology (London, England) , vol.18, no.23, pp.2573-2582, 2022

Hizal, M. Et Al. (2022) . "Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.." Future oncology (London, England) , vol.18, no.23, pp.2573-2582.

@article{article, author={Mutlu Hizal Et Al. }, title={Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.}, journal={Future oncology (London, England)}, year=2022, pages={2573-2582} }